SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q96347

Application No.: 10/591,403

REMARKS

Claims 2 is cancelled.

Claim 4 is cancelled

Claim 5 is amended. Support for the amendment can be found at least in the Examples of the present specification.

No new matter is added.

As Applicants' counsel told the Examiner, Applicants would like to supplement the remarks made in their AMENDMENT...filed August 27, 2008, with respect to the certified translation, the priority document, Japanese Patent Application No. 2004-61429 noting that claims 1, 2 and 4-16 were under examination and rejected and claims 3, 17-20, and 22-29 were withdrawn.

The first "claim" discussed below is the claim of the present application and the second "claim" mentioned is a claim of the certified translation.

Support in JP 2004-61,429 occurs as follows.

Claim 1 corresponds to claim 1 of JP '429.

Claim 2 was added at the time of PCT filing.

Claim 3 corresponds to claim 2 of JP '429.

Claims 4 and 5 were added at the time of PCT filing.

Claim 6 corresponds to claims 3 and 4 in JP '429.

Claim 7 was added at the time of PCT filing.

Claims 8-16 correspond to claims 5-13, respectively, in the JP '429.

Applicants have the following more detailed discussion regarding support for claims 2, 4, 5 and 7 in JP '429.

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q96347

Application No.: 10/591,403

Claim 2 is cancelled

Claim 4 is cancelled:

Claim 5 is limited to hydrogen


<u>Support</u>: Almost all of the compounds of the ng and Reference Examples of the priority document JP '429 provide support R5 and R6 independently representing hydrogen, but not for the other moieties. Claim 5 is amended

Claim 7: A fused heterocyclic derivative as claimed in claim 1, wherein G represents a group represented by the formula:

or a pharmaceutically acceptable salt thereof, or a prodrug thereof.

Support: Working Examples 1 and 2, at pages 78 and 79 of the priority document JP '429 provide support for claim 7:

SUPPLEMENTAL AMENDMENT UNDER 37 C.F.R. § 1.111 Attorney Docket No.: Q96347 Application No.: 10/591,403



2-(beta-D-glucopyranosyl)-4-(2-phenylethyl)benzo[b]thiophene (Compound of working Example 1)

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

SUGHRUE MION, PLLC Telephone: (202) 293-7060

Facsimile: (202) 293-7860

washington office 23373 customer number

Date: September 30, 2008

Peter D. Olexy Registration No. 24,513

Respectfully submitte